Related Experiment Video
Updated: May 24, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dabigatran (Pradaxa)
1St Vincent's Hospital, Melbourne, Australia. julescomin@gmail.com
Dabigatran (Pradaxa), a direct thrombin inhibitor, offers a predictable and potent anticoagulant effect. It may replace warfarin due to fewer side effects, interactions, and reduced monitoring needs.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Dabigatran is a novel oral anticoagulant.
- It belongs to the direct thrombin inhibitors (DTIs) class.
- Warfarin is the current standard anticoagulant.
Purpose of the Study:
- To compare dabigatran with warfarin.
- To evaluate dabigatran's efficacy and safety profile.
Main Methods:
- Clinical trials comparing dabigatran and warfarin.
- Assessment of anticoagulant effect, side effects, and monitoring requirements.
Main Results:
- Dabigatran demonstrates a more predictable and potent anticoagulant effect.
- Fewer significant side effects and drug interactions observed with dabigatran.
- Reduced need for routine monitoring compared to warfarin.
Conclusions:
- Dabigatran presents a promising alternative to warfarin.
- Its favorable profile suggests potential for widespread clinical adoption.
- Direct thrombin inhibitors offer advantages in antithrombotic therapy.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
